TABLE 3

Second contingency description of the classification nomenclature for the marketed drugs screened for MDR1 transport and inhibition used within the manuscript

		In Vivo Observation
		AUCi/AUC > 1.25 or C_max,i,ss/C_max,ss > 1.25	AUCi/AUC < 1.25 and C_max,i,ss/C_max,ss < 1.25
In vitro prediction	Cause significant exposure increase (high [I]/IC₅₀)	True positive	False positive
In vitro prediction	Do not cause significant exposure increase (low [I]/IC₅₀)	False negative	True negative
	Total	P^{^a} = 33	N^{^b} = 35	S^{^c} = 68

↵^a Number of DDI studies with clinically significant digoxin interaction (AUCi/AUC > 1.25 or C_max,i,ss/C_max,ss > 1.25).
↵^b Number of insignificant interactions with digoxin (AUCi/AUC < 1.25 and C_max,i,ss/C_max,ss < 1.25).
↵^c Total number of studies.